A survey of economists (including me).
INVESTMENT
-
AGI Utility Token Launch by AGI.Eth
By
–
Artificial General Intelligence Utility Token $AGI by AGI.Eth #AGIToken
-
AI replacing teachers: o1 model and billion-dollar investments
By
–
【 Ｌ’ＩＡ， ｕｎ ｂｏｎ ｍａîｔｒｅ ？】
L’initiative d’un collège anglais, qui va remplacer les profs par une IA, risque de faire parler. o1, le nouveau modèle d’#OpenAIdécoiffe-t-il ? 35 milliards de dollars levés en 6 mois pour l’IA #GoogleDeepMind apprend à -
Why aren’t VCs more like FanaHOVA?
By
–
If *your* investors don't do this, why not? Go ask them now: hey VC, why aren't you more like @FanaHOVA
? -
AI Node Series 0 Token Minting Launch Announced
By
–
"AI NODE SERIES 0 TOKEN" [ M i n t i n g S o o n ] This exclusive token shall be deemed exchangeable for one singular unit of "AI Nodes Series 0". Mint : https://
app.manifold.xyz/c/ainode OS : https://
opensea.io/collection/ai-
node-series-0-token
… #AINodes #AIAgents #DecentralizedAI #MontrealAI #NFT -
AI Model Drives Unexpected Interest Among Financial Professionals
By
–
Ha, will report back. Shared with bankers, consultants, lawyers, science researchers, and accountants. And compared to previous models, it felt like accountants had the biggest shift from “I don’t really care” to “wait, can you test it on XYZ?”
-
IDH-Mutation Pill Breakthrough: $480K Annual Cost Challenge
By
–
There's never been a successful Rx mutation-directed pill approved for brain cancer (gliomas and astrocytomas, grade 2) that extends progression-free survival, until the one directed vs IDH mutations came along. Unfortunately, its price is $480K/year https://
statnews.com/2024/09/13/vor
anigo-servier-brain-cancer-breakthrough/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-9DWCCc1Ks1m4ePfKrA9eh5KuIbxXyRQ6Z8kJbcMA1R_X2AF0P3L8-bZ_ZErbz7UnVirnkrwg4a01d4C2k1RSYLVARWlg&_hsmi=324444687&utm_content=324444687&utm_source=hs_email
… -
Biopharma Competition for Rare Cardiac Amyloidosis Treatment Market
By
–
Biopharma's focus on rare conditions and financial reward, exemplified:
A rare disease—primary AATR cardiac amyloidosis—is the subject of an emerging 3-way treatment competition for many $ billions per year. https://
wsj.com/health/pharma/
the-brawl-taking-shape-over-pfizers-multibillion-dollar-heart-monopoly-43a220c2?mod=Searchresults_pos1&page=1
… @pfizer @BridgeBioPharma @Alnylam -
Revenue Per Employee Metric for Solo Founders and Freelancers
By
–
Technically no employee (cant hire the 100% owner ceo) hence infinite rev/employees. But on the other hand so is every freelancer.
-
Investor enthusiasm for 3D and computer vision technologies
By
–
Low TAM tweet as always lol Cant be the only investor excited about 3d & cv